Rac1/pSTAT3 expression: a potential pharmacodynamic marker to optimize and individualize thiopurine therapy in IBD patients

Rac1/pSTAT3 expression: a potential pharmacodynamic marker to optimize and individualize thiopurine therapy in IBD patients - Rac1 PILOT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50051

Enrollment

Registered

2020-09-17

Start date

2021-01-15

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease (IBD)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age between 18 - 70 years old - Clinical, histological or endoscopic diagnosis of Crohn*s Disease, Ulcerative colitis or IBDU (IBD-unclassified) - Both hospitalized and ambulant patients are eligible

Exclusion criteria

Exclusion criteria: - current use of systemic corticosteroids - age 70 years.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the difference in Rac1 and pSTAT3 expression and activation in leucocytes of IBD patients on thiopurines and healthy volunteers.	—

Secondary

Measure	Time frame
The secondary endpoints are the degree of Rac1 and pSTAT3 expression and activation in different types of white blood cells and the differences in Rac1 and pSTAT3 expression and activation between all study groups.	—

Countries

Netherlands

Outcome results